Table 2 GI bleeding in a meta-analysis of data from 11 RCTs [39] (average duration 2.8 years).
From: Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against
Bleeding | Risk of a bleed (in 2.8 years) | Relative risk for aspirin |
|---|---|---|
Incidence of a GI bleed | ||
 - in 54,625 subjects randomised to aspirin | 8 per 1000 | RR 1.55 |
 - in 52,583 subjects randomised to placebo | 5 per 1000 | (1.32, 1.83) |
Proportion of bleeds that were fatal | ||
 - in subjects on aspirin | 4% | RR = 0.45 |
 - in subjects on placebo | 8% | (0.25, 0.80) |
Risk of a fatal bleed in trial participants | ||
 - randomised to aspirin | 3.7/10,000 | RR = 0.77 |
 - randomised to placebo | 4.7/10,000 | (0.41, 1.43) |
